Neurology Study Shows 95% Reduction in Mortality with Pyrimidine Nucleos(t)ide Therapy in Patients with TK2 Deficiency
Neurology Publication Demonstrates 95% Reduction in Mortality Risk with Pyrimidine Nucleos(t)ide Therapy in Patients with Thymidine Kinase 2 Deficiency (TK2d) UCB, a global biopharmaceutical company focused on the discovery and…
Sonrotoclax Receives Breakthrough Therapy Designation from U.S. FDA
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA, Set to Participate in Project Orbis BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused biopharmaceutical company,…
TIME Names LEQEMBI® IQLIK™ Subcutaneous Autoinjector Among 2025’s Best Inventions
LEQEMBI® IQLIK™ Subcutaneous Autoinjector Named One of TIME’s “Best Inventions of 2025” Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher…
GSK’s Shingrix Receives Approval in China to Prevent Shingles in Immunocompromised Adults Aged 18 and Older
GSK’s Shingrix Receives Approval in China to Protect Immunocompromised Adults Against Shingles GSK plc (LSE/NYSE: GSK) today announced that the China National Medical Products Administration (NMPA) has granted approval for…
DB-OTO Study Published in New England Journal of Medicine Demonstrates Significant, Lasting Gains in Hearing and Speech for Children with Profound Genetic Hearing Loss
Regeneron Presents Latest DB-OTO Data Showing Dramatic and Sustained Hearing and Speech Improvements in Children with Profound Genetic Hearing Loss Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for…
CVS Health® 2025 Rx Report Reveals How Community Pharmacies Are Evolving to Better Serve Patients
CVS Health® 2025 Rx Report Highlights the Evolution of Community Pharmacy to Meet Patient Needs CVS Health® (NYSE: CVS) today unveiled its 2025 Rx Report, Community Pharmacy Reimagined, offering a…
AstraZeneca Advances Its Mission to Redefine Cancer Care with First Results from Four Pivotal Trials Presented at ESMO 2025
AstraZeneca Showcases Transformative Oncology Pipeline with Breakthrough Data Across Multiple Cancer Types at ESMO 2025 AstraZeneca has reaffirmed its leadership in oncology innovation at the upcoming European Society for Medical…
Roche Showcases Breakthrough Data at ESMO 2025 Highlighting Scientific Advances and Transformative Progress in Cancer Care Across Multiple Tumor Types
Roche to Present Over 30 Oncology Abstracts at ESMO 2025, Showcasing Breakthroughs Across Major Cancer Types Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it will present more than 30…
FDA Approves Expanded Indication for RINVOQ® (upadacitinib) in the Treatment of Inflammatory Bowel Disease
FDA Approves Updated Indication for AbbVie’s RINVOQ® (upadacitinib) Expanding Access for Patients with Inflammatory Bowel Disease AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has…
Lilly to Present New Verzenio Data and Pipeline Updates at ESMO 2025 Annual Meeting
Data includes seven-year results from monarchE trial and updates on multiple investigational cancer therapies. Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from a…
Innate Pharma Schedules Analyst and Investor Event Focused on Lacutamab for October 28, 2025
Innate Pharma to Host Analyst and Investor Event Highlighting Lacutamab Clinical Data and Market Potential on October 28, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biopharmaceutical…
Oticara Reports Positive Phase 2 Results for Steroid Nasal Cream in Post-Surgical CRS
Oticara Reports Positive Phase 2 Results for Novel Nasal-Mucosa-Optimized Steroid Cream in Hard-to-Treat Post-Surgical Chronic Rhinosinusitis Oticara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic rhinosinusitis (CRS),…